8 Questions on Management of Chronic Coronary Disease: A Guideline Topline Quiz
Based on the updated 2023 AHA/ACC recommendations, the 9-question quiz tests what you know about the most current approaches to CCD treatment.
Updates to the 2023 practice guideline on management of patients with chronic coronary disease (CCD) issued by a joint committee of the American Heart Association and the American College of Cardiology are based on evolving evidence for incorporating new therapies and discontinuing old ones, for extending or truncating duration of therapies, and for increasing focus on the role of social determinants of health in the etiology of disease and the barriers they may pose to reducing morbidity and mortality.
The 8 questions that follow are based on the Patient Care® slide show, Management of Chronic Coronary Disease: A Guideline Topline in 10 Take-Home Messages and test what you know about the most current approaches to CCD treatment.
#1. In the management of patients with chronic coronary disease (CCD) what is the value of a patient-centered, multidisciplinary team-approach?
Compared with usual care, a patient-centered, multidisciplinary team-approach for managing patients with CCD can achieve all these improvements.
#2. In assessing patients with CCD, what is the value of patient-reported disease-specific health status?
There is no evidence for an improvement in quality of care or outcomes with routine use of patient-reported measures.
#3. Match the recommended antiplatelet/anticoagulant agent for the clinical circumstance in a patient with CCD.
Vorapaxar - add to aspirin in CCD + previous MI without stroke, TIA or ICH. P2Y12 inhibitor monotherapy - appropriate for 12 mo in CCD treated with PCI, DES after 1- to 3-mo course of DAPT. LD rivaroxaban BID - in CCD with no indication for DOAC, DAPT and high risk of recurrent ischemia but low risk for bleeding
#4. Select the clinical circumstance(s) in patients with CCD appropriate for ß-blocker treatment to reduce risk for MACE.
In patients with CCD without previous MI or LVEF ≤50%, the use of ß-blocker therapy is not beneficial in reducing MACE, in the absence of another primary indication for
ß-blocker therapy.
#5. A SGLT2 inhibitor is indicated in treatment of CCD and heart failure with LVEF ≤40% if there is comorbid diabetes: True or False?
False: A SGLT2 inhibitor is indicated in treatment of CCD and heart failure with LVEF ≤40% regardless of the presence of comorbid diabetes.
#6. When evidence on an optimal choice is unclear, a clinician should tell patient what diagnostic and treatment strategy should be followed.
False: Shared decision-making is recommended, particularly when evidence is unclear on the optimal diagnostic or treatment strategy, or when there is a significant risk or benefit trade-off.
#7. In patients with CCD, the use of nonprescription or dietary supplements, including omega-3 fatty acids, vitamins C,D,E, beta-carotene and calcium, can be beneficial to reduce the risk of cardiovascular events: True or False?
False: None of these are recommended in patients with CCD given the lack of evidence of benefit in reducing risk of cardiovascular events.
#8. Women with CCD who are contemplating pregnancy or who are pregnant should not use which of the medications above?
